Journal of Medicinal Chemistry · 2015 · 83 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationEnzyme InhibitionLigand-based DesignMolecular DockingPotency OptimizationProtein DesignProtein-ligand DockingBromodomain InhibitionBromodomain ProteinsCompound Potency OptimizationStructure - Activity Relationship OptimizationStructure-activity Relationship Guided DesignStructure-based Ligand DesignStructure-based Selectivity Design
ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphthyridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.
23
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text